Cargando…

Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents

BACKGROUND: Hepatitis C Virus (HCV) infections are blood-borne, generally chronic and are associated with increased morbidity and mortality. The aim of this study is to describe the results of therapies with direct-acting antiviral agents (DAAs) in healthcare personnel. METHODS: Secondary data analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Westermann, Claudia, Wendeler, Dana, Nienhaus, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970510/
https://www.ncbi.nlm.nih.gov/pubmed/29849741
http://dx.doi.org/10.1186/s12995-018-0197-6
_version_ 1783326145177976832
author Westermann, Claudia
Wendeler, Dana
Nienhaus, Albert
author_facet Westermann, Claudia
Wendeler, Dana
Nienhaus, Albert
author_sort Westermann, Claudia
collection PubMed
description BACKGROUND: Hepatitis C Virus (HCV) infections are blood-borne, generally chronic and are associated with increased morbidity and mortality. The aim of this study is to describe the results of therapies with direct-acting antiviral agents (DAAs) in healthcare personnel. METHODS: Secondary data analysis using data from the Statutory Accident Insurance of the Health and Welfare Service. The study surveyed DAA therapies administered to insured parties (healthcare personnel with an HCV infection recognised as an occupational disease) in Germany between 01/01/2014 and 30/11/2016. The end points were results of monitorings carried out twelve weeks after the end of treatment (SVR12), side effects and the results of the assessment of reduced work ability after treatment. Multivariate logistic regression models were constructed to model SVR12. RESULTS: The study population (n = 180) comprised 74% women, 90% of the participants had an HCV genotype 1 infection. Two-thirds had fibrosis or cirrhosis and were treatment experienced. The most common combined therapy was ledipasvir and sofosbuvir (49%). A DAA therapy with ribavirin was administered in 20% of cases, with (pegylated) interferon and ribavirin used in 2% of cases. The majority of therapies were completed without any side effects. The overall SVR12 rate was 94%. Significant independent predictor of decrease odds of SVR12 was liver cirrhosis. Positive effects on the healthcare personnel’s work ability were observed after successful therapy. CONCLUSION: High SVR12 rates were achieved in the sample population, with positive effects on their work ability. Early HCV therapy seems reasonable due to the increased chance of successful treatment of the infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12995-018-0197-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5970510
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59705102018-05-30 Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents Westermann, Claudia Wendeler, Dana Nienhaus, Albert J Occup Med Toxicol Research BACKGROUND: Hepatitis C Virus (HCV) infections are blood-borne, generally chronic and are associated with increased morbidity and mortality. The aim of this study is to describe the results of therapies with direct-acting antiviral agents (DAAs) in healthcare personnel. METHODS: Secondary data analysis using data from the Statutory Accident Insurance of the Health and Welfare Service. The study surveyed DAA therapies administered to insured parties (healthcare personnel with an HCV infection recognised as an occupational disease) in Germany between 01/01/2014 and 30/11/2016. The end points were results of monitorings carried out twelve weeks after the end of treatment (SVR12), side effects and the results of the assessment of reduced work ability after treatment. Multivariate logistic regression models were constructed to model SVR12. RESULTS: The study population (n = 180) comprised 74% women, 90% of the participants had an HCV genotype 1 infection. Two-thirds had fibrosis or cirrhosis and were treatment experienced. The most common combined therapy was ledipasvir and sofosbuvir (49%). A DAA therapy with ribavirin was administered in 20% of cases, with (pegylated) interferon and ribavirin used in 2% of cases. The majority of therapies were completed without any side effects. The overall SVR12 rate was 94%. Significant independent predictor of decrease odds of SVR12 was liver cirrhosis. Positive effects on the healthcare personnel’s work ability were observed after successful therapy. CONCLUSION: High SVR12 rates were achieved in the sample population, with positive effects on their work ability. Early HCV therapy seems reasonable due to the increased chance of successful treatment of the infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12995-018-0197-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-25 /pmc/articles/PMC5970510/ /pubmed/29849741 http://dx.doi.org/10.1186/s12995-018-0197-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Westermann, Claudia
Wendeler, Dana
Nienhaus, Albert
Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
title Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
title_full Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
title_fullStr Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
title_full_unstemmed Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
title_short Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
title_sort hepatitis c in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970510/
https://www.ncbi.nlm.nih.gov/pubmed/29849741
http://dx.doi.org/10.1186/s12995-018-0197-6
work_keys_str_mv AT westermannclaudia hepatitiscinhealthcarepersonnelsecondarydataanalysisoftherapieswithdirectactingantiviralagents
AT wendelerdana hepatitiscinhealthcarepersonnelsecondarydataanalysisoftherapieswithdirectactingantiviralagents
AT nienhausalbert hepatitiscinhealthcarepersonnelsecondarydataanalysisoftherapieswithdirectactingantiviralagents